

Antibody Engineering & Therapeutics Asia

February 24-26, 2020
The Westin Miyako Kyoto
Kyoto, Japan

**THE ONLY EVENT IN ASIA PROVIDING THE LATEST
SCIENCE, TECHNOLOGY AND PARTNERS TO
ACCELERATE ANTIBODY & PROTEIN THERAPIES,
ADCS, BISPECIFICS AND IMMUNO-ONCOLOGY**

Keynote Presentations

**Targeting Intracellular Trafficking
Pathways for the Design of Therapeutics**



Sally Ward, Ph.D.
Professor, Texas A&M
University Health Science
Center and University of
Southampton,
United Kingdom

**Novel Therapeutics Based on
Synthetic Binding Proteins**



Shohei Koide, Ph.D.
Professor of Biologics
Design, Department of
Biochemistry and Molecular
Pharmacology, New York
University School of
Medicine, USA

**Novel Bispecific $\gamma\delta$ -T cell Engagers
for the Treatment of Cancer**



Paul W.H.I. Parren, Ph.D.
EVP and Head of R&D, Lava
Therapeutics and Professor,
Leiden University Medical
Center, The Netherlands

**Novel Antibody Engineering to Improve Therapeutic Index
of Antibody Targeting Solid Tumors**



Tomoyuki Igawa, Ph.D.,
CEO and Research Head, Global Biologics
Leader, Chugai Pharmabody Research Pte. Ltd.,
Singapore

**Takeda's Vision for Antibody Drug Discovery:
An Overview of Programs and Progress**



Robert Mabry, Ph.D.
Head of Global Biologics, Takeda, USA

NEW TECHNOLOGIES, R&D ADVANCES AND CLINICAL DATA TO HELP YOU FAST-TRACK NEXT-GENERATION THERAPEUTICS TO MARKET

Antibody Engineering & Therapeutics ASIA is produced by **KNect365**, the same organizers as Antibody Engineering & Therapeutics US (San Diego) and Antibody Engineering & Therapeutics EUROPE (Amsterdam). Bringing together renowned industry and academic scientists working in the areas of antibody and protein engineering and therapeutic development, this conference provides you with the latest information about antibody-related technologies and preclinical and clinical data on antibody, ADC, bispecific and immuno-oncology programs from around the world.

Register now to learn about cutting-edge scientific advances in the field and to find the partners you need to accelerate your next-generation antibodies towards commercial success.

SCIENCE

Accelerate Your Product to Market

Hear case studies, best practices and lessons learned from global antibody, protein, ADC and Immuno-oncology developers currently in preclinical and phase 1/2/3 clinical trials.



TECHNOLOGY

Evaluate New Technologies and Services

Improve your discovery, preclinical and clinical development by meeting with global technology leaders and service providers in the exhibit hall. The exhibit hall also features peer-submitted posters that contain new research from global scientists working in antibody and protein therapeutic development.



NETWORKING

Meet Your Next Partner at Antibody Engineering & Therapeutics ASIA

Connect with antibody, protein, ADC and immuno-oncology leaders across Asia, Europe and North America during networking lunches, poster sessions, dinners and cocktail receptions.



PRELIMINARY AGENDA (Confirmed Speakers as of September 23, 2019)

CONFERENCE SESSION THEMES

- Novel Engineering and Discovery Strategies
- ADCs/Antibody-Drug Conjugates
- Bispecific Antibodies and Multi-Functional Biologics
- Immuno-Oncology
- Preclinical and Clinical Case Studies
- Delivery Strategies and Crossing/Penetrating Biological Barriers
- Engineering Strategies for TCR and CAR T Cell Therapies

February 24, 2020 (morning)

Optional Pre-Conference Workshop*

Engineering Strategies for TCR and CAR T Cell Therapies

Workshop Moderator: **Sai Reddy, Ph.D.**, Assistant Professor, Department of Biosystems Science and Engineering, **ETH Zurich/Swiss Federal Institute of Technology, Switzerland**

Confirmed Speakers:

Prime CAR Technology, a Novel Platform of T cell Therapy Against Solid Tumors

Koji Tamada, M.D., Ph.D., Professor and Chairman, Department of Immunology, **Yamaguchi University Graduate School of Medicine, Japan**

Cellular Screening Platforms for Engineering T Cell Receptors and Chimeric Antigen Receptors

Sai Reddy, Ph.D., Assistant Professor, Department of Biosystems Science and Engineering, **ETH Zurich/Swiss Federal Institute of Technology, Switzerland**

Additional Speakers to be Confirmed

**Access to pre-conference workshop require an additional fee.*

February 24 (pm) – February 26, 2020

MAIN CONFERENCE

KEYNOTE SPEAKERS

Targeting Intracellular Trafficking Pathways for the Design of Therapeutics

Sally Ward, Ph.D., Professor, **Texas A&M University Health Science Center and University of Southampton, United Kingdom**

Novel Therapeutics Based on Synthetic Binding Proteins

Shohei Koide, Ph.D., Professor of Biologics Design, Department of Biochemistry and Molecular Pharmacology, **New York University School of Medicine, USA**

Novel Bispecific $\gamma\delta$ -T cell Engagers for the Treatment of Cancer

Paul W.H.I. Parren, Ph.D., EVP and Head of R&D, **Lava Therapeutics and Professor, Leiden University Medical Center, The Netherlands**

Novel Antibody Engineering to Improve Therapeutic Index of Antibody Targeting Solid Tumors

Tomoyuki Igawa, Ph.D., CEO and Research Head, **Global Biologics Leader, Chugai Pharmabody Research Pte. Ltd., Singapore**

Takeda's Vision for Antibody Drug Discovery: An Overview of Programs and Progress

Robert Mabry, Ph.D., Head of Global Biologics, **Takeda, USA**

MAIN CONFERENCE SESSION SPEAKERS

MerTK Blockade Enhances Antitumor Immunity

Yan Wu, Ph.D., Director and Staff Scientist, **Antibody Engineering, Genentech, Inc., USA**

Effective Targeting of Tumor-specific pMHC Targets with Bispecific T cell-engaging Receptor (TCER®) Molecules

Dominik Maurer, M.D., Vice President, **Immunology, Immatix Biotechnologies GmbH, Germany**

Bispecifics and Fc Engineering

John Desjarlais, Ph.D., Chief Scientific Officer, **Xencor, Inc., USA**

Targeting bi-Specific Biologics to Disease Tissues

Lorenzo Benatui, Ph.D., Senior Principal Research Scientist, **Global Biologics, Abbvie Bioresearch Center, USA**

Synthetic DNA Technologies Enable Antibody Discovery and Optimization

Aaron K. Sato, Ph.D., CSO, **Biopharma, Twist Biopharma, a division of Twist Bioscience, USA**

New Developments in Protein Engineering

James Wells, Ph.D., Professor, **Pharmaceutical Chemistry, University of California, San Francisco, USA (Invited)**

PRELIMINARY AGENDA (Confirmed Speakers as of September 23, 2019)

A Biparatopic Agonist Antibody for OX40 That Exhibits Superior Activity Without Secondary Crosslinking

Jonathan Davis, Ph.D., Head of Discovery, **Invenra, Inc., USA**

Engineering of a T-cell Dependent Bispecific Antibody to Broaden the Therapeutic Index for Solid Tumors

Christoph Spiess, Ph.D., Senior Scientist, **Genentech, Inc., USA**

Effects of One Amino Acid Substitution on IgG Biosynthesis, Physicochemical Property, and Biologic Function

Haruki Hasegawa, Ph.D., Principal Scientist, Biologics - Therapeutic Discovery, **Amgen, USA**

Functional Screening of the B-cell Repertoire and Development of Anti-Infective mAbs

Vu Truong, Ph.D., Founder, Chief Executive Officer and Director, **Aridis Pharmaceuticals, USA**

Efgartigimod and Clinical Trials in MG and ITP

Hans de Haard, Ph.D., Chief Scientific Officer, **Argenx, Belgium**

Deep Learning Enables Therapeutic Antibody Optimization in Mammalian Cells

Sai Reddy, Ph.D., Assistant Professor, Department of Biosystems Science and Engineering, **ETH Zurich/Swiss Federal Institute of Technology, Switzerland**

Updates on the Discovery and Development of Antibody-Drug Conjugates

Yuuri Hashimoto, Ph.D., Oncology Research Laboratories I, Oncology Function, R&D Division, **Daiichi Sankyo Co., Ltd., Japan**

Progress on the Development of a Novel Anti-Tau Antibody

Teiji Kimura, Chief Discovery Officer, **Eisai Neurology Business Group, Japan**

Enzyme Transport Vehicle (ETV): A Novel Brain Delivery Platform for Enzyme Replacement Therapies

Mark Dennis, Fellow, **Denali Therapeutics, USA (Invited)**

Innovative Concepts for Therapeutic Approaches in Autoimmune Disease and Immuno-oncology

Shiro Shibayama, Ph.D., Executive Director, Research Center of Immunology, Tsukuba Institute, **ONO Pharmaceutical Co., LTD. (Invited)**

Novel Conjugation Technology for ADCs

Timothy Lowinger, Chief Scientific Officer, **Mersana Therapeutics (Invited)**

ADC Development: Clinical Advances and Novel Strategies

Roger Beerli, Ph.D., Chief Scientific Officer, **NBE-Therapeutics AG, Switzerland**

Development of ADCs for Novel Indications

Adrian Hobson, Research Fellow, Global Biologics - Antibody Drug Conjugates, **Abbvie, USA (Invited)**

Benchmarking T Cell-Redirecting Therapies for Cancer: Comparing CD3-Bispecifics and CAR T Cells

David J. DiLillo, Ph.D., Senior Staff Scientist, Immuno-Oncology, **Regeneron Pharmaceuticals, USA (Invited)**

A Novel Antibody Technology

Atsushi Suwa, Scientist, **Dainippon Sumitomo, Japan**

DARPin Technology and Alternative Scaffolds

Birgit Dreier, Senior Scientist and Group Leader, **University of Zürich, Switzerland**

ANTIBODY ENGINEERING & THERAPEUTICS ASIA 2020 ADVISORY BOARD

Tomoyuki Igawa, Ph.D., CEO and Research Head, **Chugai Pharmabody Research Pte. Ltd., Singapore**

Sai Reddy, Ph.D., Assistant Professor, Department of Biosystems Science and Engineering, **ETH Zurich/Swiss Federal Institute of Technology, Switzerland**

Yong-Sung Kim, Ph.D., Professor, Departments of Molecular Science and Technology, and Applied Chemistry and Biological Engineering, **Ajou University, South Korea**

Qing Li, Ph.D., Scientist I, **MedImmune, USA**

Karthik Viswanathan, Director, Research, **Visterra, Inc., USA**

Jijie Gu, Ph.D., Chief Scientific Officer and Executive Vice President, **WuXi Biologics, China**

Chengbin Wu, Ph.D., Chief Executive Officer, **Shanghai EpimAb Biotherapeutics Inc., China**

Andrew Bradbury, M.D., Ph.D., Chief Scientific Officer, **Specifica**


Media Partners:



AntibodyTherapeutics



BECOME A SPONSOR AND EXHIBITOR



Connect face-to-face with 100+ highly influential scientists, engineers and executives from industry and academia

with the budget and authority to recommend, specify and approve the purchase of products and services to accelerate antibody research, discovery efforts and clinical programs.

Showcase your products and services directly to this audience of antibody researchers and senior decision makers through:

- **Exhibit Booth Packages – only 6 left!**
- **Scientific Briefings – only 4 left!**
- **Custom Emails**
- **Branding touches – lanyards, conference totes, pad, pens, etc.**

A wide variety of options are available to help you meet your company objectives before, during and after the conference.

Confirmed Sponsors and Exhibitors

(As of September 23, 2019)



CONNECT WITH 100+ BUYERS RESERVE YOUR EXHIBIT BOOTH OR SPONSORSHIP TODAY!

For more information on how you can connect with these key buyers, contact:

Kristin Skahan • T: +1-857-504-6730 • E: kristin.skahan@knect365.com

THREE WAYS TO REGISTER

EASIEST:
WWW.ANTIBODYENGASIA.COM

CALL
+44 (0)20 3377 3279

EMAIL
LS.Registrations@KNect365.com

INDUSTRY RATES	SAVE 600 USD October 18, 2019	Standard Rate
Main Conference + Pre-Conference Workshop (3-Day Access - Valid Feb. 24 morning through Feb. 26 afternoon)	\$2,299	\$2,899
Main Conference ONLY (2.5 Day Access - Valid Feb. 24 afternoon through Feb. 26 afternoon)	\$1,699	\$2,299
ACADEMIC/GOVERNMENT RATES*	SAVE 400 USD October 18, 2019	Standard Rate
Main Conference + Pre-Conference Workshop (3-Day Access - Valid Feb. 24 morning through Feb. 26 afternoon)	\$899	\$1,299
Main Conference ONLY (2.5 Day Access - Valid Feb. 24 afternoon through Feb. 26 afternoon)	\$699	\$1,099
ADDITIONAL OPTIONS		
Industry Poster	\$150	
Academic/Government Poster	\$0	

*Academic/Government rates are extended to full-time employees of government, universities and university-affiliated hospitals only.
All prices noted above are in USD. 8% Japanese Consumption Tax (JCT) to be applied to all orders.



Conference Venue & Accommodation The Westin Miyako Kyoto

1 Awataguchi Kachocho, Higashiyama-ku, Kyoto 605-0052, Japan

Tel: +81-75-771-7111 • Fax: +81-75-751-2490


[Take Advantage of Our Discounted Hotel Rooms](#)

Group Rates

Register a Group of 3+ and Save \$200 USD/Person.

To register your group, please contact Jessica Purnell at Jessica.Purnell@KNect365.com or +44 (20) 7551 952.

*Group rates are for industry only



Present a Scientific Poster at Antibody Engineering & Therapeutics Asia

Share your company's scientific research by presenting a poster at Antibody Engineering & Therapeutics Asia. Be sure to sign up for a poster space when you register and submit your abstract online by January 24, 2020. Submit your poster abstract at WWW.ANTIBODYENGASIA.COM